Japan-based medtech company Olympus Corporation has announced the launch of THUNDERBEAT™ II, the next generation hybrid energy device for soft tissue management, designed to deliver faster, more hemostatic dissection and large vessel transection in both laparoscopic and open surgery.
THUNDERBEAT™ II will become commercially available in Europe starting October 2025, with a subsequent launch in Japan later this year. A global rollout, including the United States and other regions, will follow, subject to regulatory approvals including product registration and market clearance.
THUNDERBEAT II is part of Olympus’ THUNDERBEAT series, a line of pioneering hybrid energy devices designed for use in both laparoscopic and open surgery. Compared to the previous generation, THUNDERBEAT II delivers faster hemostatic dissection and more secure vessel sealing, featuring a refined probe design that minimises thermal impact on surrounding tissue. Additionally, the versatility of three energy modes — including a new ultrasonic energy setting — supports surgeons in technically challenging procedures, enabling them to adapt to changing clinical conditions without interrupting the procedure to exchange instruments. THUNDERBEAT II offers surgeons even more features and greater versatility than ever before.
It features three output modes: hybrid energy (SEAL & CUT Mode) for fast, precise hemostatic dissection compared to its previous model; advanced bipolar energy (SEAL Mode) for vessel pre-sealing and spot hemostasis; and newly added ultrasonic energy (ULTRASONIC Mode) for fine dissection in anatomical spaces when cutting without bipolar energy is required.
